Data from a recent meta-analysis has shown that in spite of the fact that TET2 mutations had no significant prognostic value on myelodysplastic syndromes, the response rates to hypomethylating agents were significantly different between patients with and without TET2 mutations (77). This evidence concerns the gene TET2 and myelodysplastic syndrome.